A PHASE 1, RANDOMIZED, OPEN-LABEL, THREE-PERIOD CROSSOVER STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF SISUNATOVIR FOLLOWING SINGLE ORAL DOSE OF DIFFERENT FORMULATIONS UNDER FED AND FASTED CONDITIONS IN HEALTHY ADULT PARTICIPANTS
Latest Information Update: 08 May 2025
At a glance
- Drugs Sisunatovir (Primary)
- Indications Renal failure; Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 20 Mar 2024 Status changed from active, no longer recruiting to completed.
- 07 Feb 2024 Planned End Date changed from 18 Mar 2024 to 26 Feb 2024.
- 07 Feb 2024 Planned primary completion date changed from 18 Mar 2024 to 26 Feb 2024.